Excipient selection in parenteral formulation development

Pharma Times

Volumn 45, Issue 3, 2013, Pages 65-77

  Pramanick, Sougata ^a   Singodia, Deepak ^a   Chandel, Vikas ^a  

^a Emcure Pharmaceuticals Limited   (India)

Author keywords

Excipients; Formulation development; Lyophilized; Parenterals; Suspension

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMIFOSTINE; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; AZITHROMYCIN; AZTREONAM; BUFFER; BULKING AGENT; CARMUSTINE; CEFAZOLIN; CHLOROTHIAZIDE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DANTROLENE; DAUNORUBICIN; DISPERSANT; DRUG PRESERVATIVE; EXCIPIENT; LACTOSE; MACROGOL; MANNITOL; POVIDONE; PROSTAGLANDIN E1; PROSTAVASIN; SOLUBILIZER; SOLVENT; SUCROSE; SURFACTANT; UNINDEXED DRUG; WETTING AGENT;

ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; DRUG SOLUBILITY; DRUG STABILITY; ERECTILE DYSFUNCTION; FLOCCULATION; FREEZE DRYING; PHYSICAL CHEMISTRY; RHEUMATOID ARTHRITIS; SUSPENSION; TEMPERATURE;

EID: 84875500888     PISSN: 00316849     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Robertson MI. Regulatory issues with excipients. Int. J. Pharm. 1999; 187: 273-276.
2. Nema S, Brendel RJ. Excipients and their role in approved injectable products: current usage and future directions. PDA J Pharm Sci Technol. 2011; 65(3):287-332.
3. BP. Parenteral Preparations. In British Pharmacopoeia, Stationary Office London. 1999; Vol. II: 1575.
4. th edition: 1765.
5. Jennings TA. Effect of formulation on lyophilization, part 1. IVD Technology Magazine, 1997.
6. Pikal MJ. Freeze-drying of proteins. Part II: Formulation selection. BioPharm. 1990; 3:26-30.
7. Crowe JH, Hoekstra FA, Crowe LM. Anhydrobiosis, Annu. Rev. Physiol. 1992; 54: 579-599.
8. Crowe LM, Reid DS, Crowe JH. Is trehalose special for preserving dry materials? Biophys. J. 1996; 71: 2087-2093
9. Townsend MW, Deluca MEPP. Use of Lyoprotectants in the Freeze-Drying of a Model Protein, Ribonuclease A. PDA Journal of Pharmaceutical Science and Technology. 1988; 42 (6): 190-199.
10. Richard LR, Krishnan, SK, William JC. Development of Stable Lyophilized Protein Drug Products. Current Pharmaceutical Biotechnology. 2012; 13(3): 471-496
11. Frank KBA. Understanding Lyophilization Formulation Development. Pharmaceutical Tech. Lyophilization. 2004, 10-18
12. Meister E, Ellnain M, Gieseler H. Collapse temperature measurement by freeze-dry microscopy and transferability to freeze drying processes: influence of solute concentration on collapse behavior and effect on cycle design. AAPS annual meeting and exposition. Oct 29 - Nov 2, 2006, San Antonio, Texas, USA
13. Amin K, Dannenfelser RM, Zielinski J, Wang B. Lyophilization of polyethylene glycol mixtures. J Pharm Sci. 2004; 93(9):2244-9.
14. Chang BS, Randall CS. Use of subambient thermal analysis to optimize protein lyophilization. Cryobiology. 1992; 29: 632-656.
15. MacKenzie AP. The physico-chemical basis of the freeze drying process. Dev Biol Std. 1976; 36: 51-67.
16. Franks F. Freeze drying: From empiricism to predictability. Cryo-Letters. 1990; 11: 93-110.
17. Her LM, Nail SL. Measurement of glass transition temperatures of freeze-concentrated solutes by differential scanning calorimetry. Pharm Res. 1994; 11: 54-59.
18. MacKenzie AP. Basic principles of freeze drying for pharmaceuticals. Bull Par Drug Assoc. 1966; 20: 101-129.
19. Bellows RJ, King CJ. Freeze drying of aqueous solutions: Maximum allowable operating temperature, Cryobiology. 1972; 9: 559-561.
20. Shalaev EY, Kanev AN. Study of the solid-liquid state diagram of the water-glycine-sucrose system, Cryobiology. 1994; 31: 374-382.
21. Pikal MJ. Freeze drying, in Swarbrick J and Boylan JC (eds): Encyclopedia of Pharmaceutical Technology, Marcel Dekker Inc., New York, NY, 1992; 6: 275-303.
22. Trissel LA. Handbook on injectable drugs, American society of Hospital Pharmacists, Inc., 8th edition, 1994.
23. Montvale NJ. Physicians Desk Reference. Medical Economics Company Incorporation, 53rd edition, 1999.
24. Shalaev EY. The impact of buffer on processing and stability of freeze-dried dosage forms. Am Pharm Rev. 2005; 8: 80-87.
25. Shalaev EY, Wang W, Gatin LA. Rational choice of excipients for use in lyophilized formulations. in McNally EJ and Hastedt JE (eds): Protein formulation and delivery. Informa Healthcare, New York, NY, 2008; 175; 197-217.
26. Gomez G, Pikal MJ, Rodriguez-Hornedo N. Effect of initial buffer composition on pH changes during far-fromequilibrium freezing of sodium phosphate buffer solutions. Pharm Res. 2001; 18: 90-97.
27. Shalaev EY, Johnson-Elton TD, Chang L, et al. Thermophysical Properties of Pharmaceutically Compatible Buffers at Sub-Zero Temperatures: Implications for Freeze-Drying. Pharm Res. 2002; 19: 195-201.
28. Song Y, Schowen RL, Borchardt RT, Topp EM, Formaldehyde production by Tris buffer in peptide formulations at elevated temperature, 2001, J Pharm Sci 90:1198-1203
29. Costantino HR, Griebenow K, Langer R. On the pH memory of lyophilized compounds containing protein functional groups. Biotechnol Bioeng. 1997; 53: 345-348.
30. Lai MC, Topp EM. Solid-state chemical stability of proteins and peptides. J Pharm Sci. 1999; 88: 489-500.
31. Liu WR, Langer R, Klibanov AM. Moisture-induced aggregation of lyophilized proteins in the solid state. Biotechnol Bioeng. 1991; 37: 177-184.
32. Nema S, Ronald J. Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions PDA Journal of Pharmaceutical Science and Technology. 2011; 65 (3); 287-332.
33. Brewster ME, Simpkins JW, Hora MS. The potential use of cyclodextrins in parenteral formulations. J Parenter Sci Technol. 1989; 43:231-240.
34. Liberman A, Martin M, Rieger B. Gilbent's Pharmaceutical Dosage forms Dispersed systems. Marcel Dekker. 1996;2:285.
35. Quay JF, Stucky JF. Non aqueous cephalosporin suspension for parenteral Administration. J. Pharm. Sci. 1989; 11:1602-1606.
36. Liberman A, Martin M, Rieger B. Gilbent's Pharmaceutical Dosage forms Dispersed systems. Marcel Dekker. 1996;2:285.
37. Brazeau GA, Fung HL. Mechanics of retaining kinase release from isolated rat skeletal muscles damaged by propylene glycol and ethanol. J. Pharm. Sci. 1990: 79: 397.
38. Avis KE. Parenteral preparations in Remingtons pharmaceutical science. 16th ed. Mark publishing; 1980: 1467.
39. British Pharmacopoeia, London, Appendix XVIC, 1993: A191-A192.
40. Huettenrauch R. Stabilization of suspension. DD 209970. Al 840530. 8PP. 1989
41. Nema S, Brendel RJ, Richard W. Excipients: Parenteral Dosage Forms and Their Role. Encyclopedia of Pharmaceutical Technology, Informa Healthcare USA. 2007; 1622-1645.
42. Excipients in Pharmaceutical Dosage Forms: The Challenge of the 21st Century. Nice, France, May 1998:14 -15.
43. Excipients in the Label and Package Leafet of Medicinal Products for Human Use. In European Commission; Guidelines Medicinal products for human use Safety, environment and information 2003; 3B.
44. CPMP. Note for Guidance on the Use of Bovine Serum in the Manufacture of Human Biological Medicinal Products. In CPMP/ BWP/1793/02: 2003.
45. Matthews B. BSE/TSE risks associated with active pharmaceutical ingredients and starting materials: the situation in Europe and the global implications for healthcare manufacturers. PDA J. Pharm. Sci. Technol. 2001; 55 (5): 295-328.
46. Guidelines Medicinal products for human use Safety, environment and information Excipients in the label and package leafet of medicinal products for human use July 2003. Volume 3B. European Commission Enterprise Directorate-General Brussels, ENTR/F2/BL D(2003)
47. Frank DW, Gray JE, Weaver RN. Cyclodextrin nephrosis in the rat. Am. J. Pathol. 1976; 83 (2): 367-382.
48. Middleton JC, Tipton AJ. Synthetic biodegradable polymers as medical devices. Medical Plastics Biomaterials. 1998; 5 (2): 30-39.
49. Pettit DK, Lawter JR, Huang WJ, et al. Characterization of poly(glycolide-co-D,L-lactide)/poly(D,L-lactide) microspheres for controlled release of GM-CSF. Pharm. Res.1997; 14 (10): 1422-1430.
50. Sullivan SA, Gilley RM, Gibson JW, et al. Delivery of taxol and other Antineoplastic agents from a novel system based on sucrose acetate isobutyrate. Pharm. Res. 1997; 14 (11): 291.